Objectives We investigate screening sensitivity, transition probability and sojourn time in lung cancer screening for male heavy smokers using the Mayo Lung Project data. We also estimate the lead time distribution, its property, and the projected effect of taking regular chest X-rays for lung cancer detection. Methods We apply the statistical method developed by Wu et al. [1] using the Mayo Lung Project (MLP) data, to make Bayesian inference for the screening test sensitivity, the age-dependent transition probability from disease-free to preclinical state, and the sojourn time distribution, for male heavy smokers in a periodic screening program. We then apply the statistical method developed by Wu et al. [2] using the Bayesian posterior samples from the MLP data to make inference for the lead time, the time of diagnosis advanced by screening for male heavy smokers. The lead time is distributed as a mixture of a point mass at zero and a piecewise continuous distribution, which corresponds to the probability of no-early-detection, and the probability distribution of the early diagnosis time. We present estimates of these two measures for male heavy smokers by simulations. Results The posterior sensitivity is almost symmetric, with posterior mean 0.89, and posterior median 0.91; the 95% highest posterior density (HPD) interval is (0.72, 0.98). The posterior mean sojourn time is 2.24 years, with a posterior median of 2.20 years for male heavy smokers. The 95% HPD interval for the mean sojourn time is (1.57, 3.35) years. The age-dependent transition probability is not a monotone function of age; it has a single maximum at age 68. The mean lead time increases as the screening time interval decreases. The standard error of the lead time also increases as the screening time interval decreases. Conclusion Although the mean sojourn time for male heavy smokers is longer than expected, the predictive estimation of the lead time is much shorter. This may provide policy makers important information on the effectiveness of the chest X-rays and sputum cytology in lung cancer early detection. Published by Elsevier Ireland Ltd.
Objectives-The association between screening sensitivity, transition probability, and individual's age in FOBT for colorectal cancer are explored, for both males and females.Methods-We apply the statistical method developed by Wu et al.[1] using the Minnesota colorectal cancer study group data, to make Bayesian inference for the age-dependent screening test sensitivity, the age-dependent transition probability from disease-free to preclinical state, and the sojourn time distribution, for both male and female participants in a periodic screening program. This gives us more information on the effectiveness of the fecal occult blood test in colorectal cancer detection.Results-The sensitivity appears to increase with age for both genders. However, the posterior mean sensitivity is not monotonic with age for males; it has a peak around age 74. The standard errors of the sensitivity are not monotone either; there is a minimum at age 69 for males and at age 78 for females. The age-dependent transition probability is not a monotone function of age; it has a single maximum at age 72 for males and a single maximum at age 75 for females. The age dependency seems more dramatic for females than for males. The posterior mean sojourn time is 4.08 years for males and 2.41 years for females, with a posterior median of 1.66 years for males and 1.88 years for females. The 95% highest posterior density (HPD) interval is (0.97, 20.28) for males and (1.15, 5.96) for females, which are very large ranges, especially for males. The reason might be that there were fewer men than women in the annual screening program.Conclusion-Reliable estimates of age-dependent sensitivity and transition probability are of great value to policy-makers regarding the initial age for colorectal cancer screening exams. We found that the mean sojourn time for males is much longer than that for females, which may imply that FOBT screening for colorectal cancer may be more effective for males than for females.
BackgroundWhen evaluating cancer screening it is important to estimate the cumulative risk of false positives from periodic screening. Because the data typically come from studies in which the number of screenings varies by subject, estimation must take into account dropouts. A previous approach to estimate the probability of at least one false positive in n screenings unrealistically assumed that the probability of dropout does not depend on prior false positives.MethodBy redefining the random variables, we obviate the unrealistic dropout assumption. We also propose a relatively simple logistic regression and extend estimation to the expected number of false positives in n screenings.ResultsWe illustrate our methodology using data from women ages 40 to 64 who received up to four annual breast cancer screenings in the Health Insurance Program of Greater New York study, which began in 1963. Covariates were age, time since previous screening, screening number, and whether or not a previous false positive occurred. Defining a false positive as an unnecessary biopsy, the only statistically significant covariate was whether or not a previous false positive occurred. Because the effect of screening number was not statistically significant, extrapolation beyond 4 screenings was reasonable. The estimated mean number of unnecessary biopsies in 10 years per woman screened is .11 with 95% confidence interval of (.10, .12). Defining a false positive as an unnecessary work-up, all the covariates were statistically significant and the estimated mean number of unnecessary work-ups in 4 years per woman screened is .34 with 95% confidence interval (.32, .36).ConclusionUsing data from multiple cancer screenings with dropouts, and allowing dropout to depend on previous history of false positives, we propose a logistic regression model to estimate both the probability of at least one false positive and the expected number of false positives associated with n cancer screenings. The methodology can be used for both informed decision making at the individual level, as well as planning of health services.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.